ClinicalTrials.gg
Active, not recruitingNCT07209358Updated Nov 2, 2026

EDX110 Randomized Control Trial for Treatment of DFUs

An interventional study of EDX110 in Wound Heal and Diabetic Foot Ulcer, sponsored by ConvaTec Inc.. Active, not recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by ConvaTec Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now Active, not recruitingFirst site in Puerto Rico+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
24th of 322
300 · median 60
Started
2025
with 29 others
No phase
186 of 381
38 open now
Primary completion
2027-03
later than 55 of 83 live
Registered
360th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 24th largest by enrollment of the 322 interventional ones that give a count, is one of 30 that started in 2025, is one of 186 with no phase, reaches primary completion later than 55 of the 83 other live ones, and was the 360th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.

03

Conditions studied

  • Wound Heal
  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • Hard to heal wounds
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study.
  • The participant must have an index ulcer meeting the following characteristics:

    1. Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory.
    2. Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue.
    3. Located on the anatomical foot; defined as distal to the medial or lateral malleolus.
  • Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema >0.5 but \<2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge.
  • Ulcer duration at randomization must be present for ≥1 month but less than \<24 months in duration.
  • Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2.
  • If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:

    1. The ulcer with the largest wound area, as long as it meets all other criteria.
    2. ≥3cm distance from any other ulcer on the affected limb
  • Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history).
  • HgbA1c \<12% (NGSP) OR 108 mmol/mol (IFCC) OR average blood glucose 298 mg/DL.
  • Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD).
  • Participants are required to have either.

    1. Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5
    2. OR Dorsum transcutaneous oxygen test (TcPO2): >40 mm/Hg

Exclusion criteria

Exclusion Criteria:

  • Participants with wounds that have any of the following characteristics:

    1. Wagner Grade 2 - ulcers extend into tendon, bone, or capsule
    2. Grade 3 - deep ulcer with osteomyelitis, or abscess
    3. Grade 4 - partial foot gangrene
    4. Grade 5 - whole foot gangrene
  • Infections that are classified as:

    1. PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone).
    2. PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome [SIRS]).
    3. In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture/histopathology of a bone specimen
    4. OR Cellulitis/lymphangitis/soft tissue gas or necrotizing fasciitis originating from the wound site.
  • Tunnelling, Cavity or undermining wounds.
  • Known or suspected local skin at the site of the ulcer.
  • A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis).
  • Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities.
  • Active Charcot deformity.
  • Wound duration >2 years.
  • Participants receiving any of the following prior therapies. In the last 30 days:

    1. Has required systemic >10mg/kg/day OR
    2. Participant has required Chemoradiation (chemotherapy and/or radiation therapy) to treat cancer and is OR
    3. Participant is anticipated to require such medications during the study period.
    4. Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix).
    5. Has undergone any amputation to the affected leg.
  • Known to constituents of the product.
  • Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator.
  • Women of childbearing age (women aged \<55 years who have not undergone menopause) who are:

    1. Pregnant at time of enrolment
    2. Breast-feeding
  • Concurrent enrolment in any other study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Active comparator
    EDX110 with Standard of Care (SOC)

    Diabetic Foot Ulcer (DFU) DFU treatment with EDX110 wound dressing and SOC

    Device: EDX110

  • No intervention
    Standard of Care (SOC)

    Diabetic Foot Ulcer (DFU) DFU treatment with using only traditional Standard of Care (SOC)

Interventions

  • DeviceEDX110

    EDX110 wound dressing system EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement

06

What researchers measure

Primary outcomes

  1. Wound Closure

    Incidence of complete wound closure at 16 weeks in participants with DFU who are receiving standard of care (SOC) versus participants receiving EDX110 and SOC. Wound closure is defined as 100% reepithelialization of the wound without drainage.

    Time frame: 16 Weeks

Secondary outcomes

  1. Time to Wound Closure

    Time to complete wound closure during treatment period in participants with DFU who are receiving standard of care (SOC) versus participants receiving EDX110 and SOC.

    Time frame: 16 Weeks

  2. Percent Area Reduction 4 weeks

    The difference in the mean Percent Area of Reduction (PAR) at 4 weeks compared to baseline in participants with DFU who are receiving standard of care (SOC) versus participants receiving EDX110 and SOC.

    Time frame: 4 Weeks

  3. Percent Area Reduction 16 weeks

    The difference in the mean Percent Area of Reduction (PAR) at 16 weeks compared to baseline in participants with DFU who are receiving standard of care (SOC) versus participants receiving EDX110 and SOC.

    Time frame: 16 weeks

  4. Wound closure at 24 weeks

    Incidence of complete wound closure at 24 weeks in participants with DFU who are receiving standard of care (SOC) versus participants receiving EDX110 and SOC. Wound closure is defined as 100% reepithelialization of the wound without drainage.

    Time frame: 24 weeks

Other outcomes

  1. Hospitalizations relating to the target ulcer

    Determine if the use of EDX110 leads to a reduction of the patient being hospitalized due to adverse events or complications related to their target ulcer.

    Time frame: 16 Weeks

  2. Amputations relating to the target ulcer

    Determine if use of EDX110 leads to reduction in the occurrences of an amputation of the leg, foot, or toes due to the target ulcer.

    Time frame: 16 Weeks

  3. Systemic antibiotic usage during the 16-week treatment period

    Determine if the use of EDX110 reduces the number of antibiotic treatments provided during the 16-week treatment period to the participant.

    Time frame: 16 Weeks

  4. Systemic antibiotic usage in the full 24-week study period

    Determine if the use of EDX110 reduces the number of antibiotic treatments provided during the 24-week treatment period to the participant.

    Time frame: 24 Weeks

  5. Incidence of new infections or increasing severity of infections during the 24-week study period

    Determine if the use of EDX110 reduces the number of infections in the index ulcer throughout the study period.

    Time frame: 24 Weeks

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 7, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Mar 31, 2027was Dec 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 2, 2026
Sites
7 sites added, 1 site removed — first site in Puerto Rico
Show 7 added (6 United States, 1 Puerto Rico)
  • Advanced Foot Care · Phoenix, United States
  • Keck Medicine of USC · Los Angeles, United States
  • Herco Medical Center · Flagami, United States
  • Gateway Clinical Trials · O'Fallon, United States
  • OHSU · Portland, United States
  • University of Texas Health Science Center · San Antonio, United States
  • Clinical Research Management Group · Mayagüez, Puerto Rico
Show 1 removed
  • Axentra Bio · Phoenix, United States
Nov 2, 2026
Primary completion
Dec 1, 2026→Mar 31, 2027
Nov 2, 2026
Study completion
Dec 31, 2026→Jun 30, 2027
Nov 2, 2026
Enrollment
298 (estimated)→300 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Active, not recruiting
    7 sites added, 1 site removed — first site in Puerto Rico
    Show 7 added (6 United States, 1 Puerto Rico)
    • Advanced Foot Care · Phoenix, United States
    • Keck Medicine of USC · Los Angeles, United States
    • Herco Medical Center · Flagami, United States
    • Gateway Clinical Trials · O'Fallon, United States
    • OHSU · Portland, United States
    • University of Texas Health Science Center · San Antonio, United States
    • Clinical Research Management Group · Mayagüez, Puerto Rico
    Show 1 removed
    • Axentra Bio · Phoenix, United States
    Primary completion Dec 1, 2026→Mar 31, 2027
    Study completion Dec 31, 2026→Jun 30, 2027
    Enrollment 298 (estimated)→300 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07209358
Lead sponsor
ConvaTec Inc.
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Oct 30, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Christina M Mastandrea, MS
study director · ConvaTec Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion